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Staphylococcus aureus skin infections represent a significant public health threat because of the emergence of
antibiotic-resistant strains such as methicillin-resistant S. aureus (MRSA). As greater understanding of protective
immune responses and more effective antimicrobial therapies are needed, a S. aureus skin wound infection
model was developed in which full-thickness scalpel cuts on the backs of mice were infected with a
bioluminescent S. aureus (methicillin sensitive) or USA300 community-acquired MRSA strain and in vivo
imaging was used to noninvasively monitor the bacterial burden. In addition, the infection-induced
inflammatory response was quantified using in vivo fluorescence imaging of LysEGFP mice. Using this model,
we found that both IL-1a and IL-1b contributed to host defense during a wound infection, whereas IL-1b was
more critical during an intradermal S. aureus infection. Furthermore, treatment of a USA300 MRSA skin infection
with retapamulin ointment resulted in up to 85-fold reduction in bacterial burden and a 53% decrease in
infection-induced inflammation. In contrast, mupirocin ointment had minimal clinical activity against this
USA300 strain, resulting in only a 2-fold reduction in bacterial burden. Taken together, this S. aureus wound
infection model provides a valuable preclinical screening method to investigate cutaneous immune responses
and the efficacy of topical antimicrobial therapies.
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INTRODUCTION
Staphylococcus aureus is the most common cause of skin and
soft-tissue infections, such as impetigo, cellulitis, folliculitis/
furunculosis, and abscesses (McCaig et al., 2006; Moran
et al., 2006). These infections have become a significant
public health problem as they result in over 11 million
outpatient and emergency room visits and B500,000
hospitalizations per year in the United States (McCaig
et al., 2006). Furthermore, the treatment of S. aureus
infections has been complicated by the widespread emer-
gence of antibiotic-resistant strains such as methicillin-
resistant Staphylococcus aureus (MRSA) (Boucher and Corey,
2008; Deleo and Chambers, 2009).
Systemic antibiotic treatment is frequently required to treat
S. aureus skin infections, especially in cases of community-
acquired MRSA (CA-MRSA) infections. One strain, USA300,
is responsible for 490% of all CA-MRSA skin and soft-tissue
infections in the United States (King et al., 2006; Jones et al.,
2007; Tenover and Goering, 2009). USA300 can cause
serious and necrotizing skin infections, which are likely
because of the expression of cytolytic toxins such as PVL
(Panton–Valentine leukocidin), a-toxin and other cytolytic
toxins (Wang et al., 2007; David and Daum, 2010; Kennedy
et al., 2010).
In addition to systemic antibiotics, topical antibiotic
therapy can have an important adjunctive role in the
treatment of superficial S. aureus skin infections, such as
impetigo, infected lacerations, and in areas with poor blood
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supply (i.e., diabetic foot ulcers) as well as in the prevention
of postsurgical wound infections (Daum, 2007). Furthermore,
topical antibiotics can be used alone for uncomplicated
superficial skin infections such as impetigo and infected
lacerations, as a higher local concentration of the antibiotic
reaches the site of infection and reduces the potential for
systemic side effects (Elston, 2007). Mupirocin is the most
commonly used prescription-strength topical antibiotic to
treat S. aureus skin infections (Daum, 2007). In addition,
mupirocin is frequently used for decolonization of S. aureus
and MRSA nasal carriage (Bode et al., 2010). However, S.
aureus strains with low- and high-level mupirocin resistance
have been reported, which contributes to treatment failures
(Thomas et al., 2010). Retapamulin is a newer topical
antibiotic agent, which has been shown to exhibit potent
antibacterial activity against S. aureus in vitro and in vivo
(Yang and Keam, 2008). However, the efficacy of topical
retapamulin against an important CA-MRSA strain, such as
USA300, has not been well characterized.
Because of this rapidly emerging epidemic and the
growing problem of antibiotic resistance, there is a great
need for new antibiotic therapies as well as an increased
understanding of protective immune responses to help design
immune-based therapeutic strategies. Although human skin
equivalent culture systems can be used to monitor bacterial
colonization and infection in vitro (Holland et al., 2008), a
preclinical in vivo animal model system is required by the
FDA (Food and Drug Administration) to determine the
efficacy of new antimicrobial treatments before more
extensive studies in larger animals or human subjects.
Previous animal models to evaluate topical treatment of
superficial S. aureus infections include a burned skin model
(Rode et al., 1988; Heggers et al., 1989), a skin surgical/
suture wound (McRipley and Whitney, 1976; Rittenhouse
et al., 2006), and a tape-stripping model (Kugelberg et al.,
2005; Hahn et al., 2009). In each of these models, euthanasia
is required to determine the ex vivo bacterial burden using
colony counts, and consequently, large numbers of animals
are required to determine treatment efficacy. In this study, we
set out to develop a S. aureus skin infection model utilizing
advanced techniques of in vivo imaging to noninvasively and
longitudinally monitor the bacterial burden and infection-
induced inflammation without the need for euthanasia.
RESULTS
In vivo bioluminescence imaging to measure bacterial burden
To model a S. aureus skin wound infection, scalpel cuts
on the backs of mice were inoculated with a bioluminescent
S. aureus strain (SH1000). The in vivo bacterial burden was
determined by measuring the S. aureus bioluminescence
signals in anesthetized mice (Xenogen IVIS; Caliper Life
Sciences, Hopkinton, MA). To determine the optimal
bacterial inoculum that produced a consistent skin wound
infection, increasing inocula of S. aureus (2 105, 2106,
and 2107 colony-forming units (CFUs) per 10 ml) or no
bacterial inoculation (none) were evaluated (Figure 1).
2107 CFUs induced the largest lesions and 2 106 CFUs
induced intermediate lesion sizes, which were statistically
greater than those of uninfected mice (Figure 1a and b). In
contrast, 2 105 CFUs induced lesions virtually identical to
those of uninfected mice. Similarly, 2107 CFUs induced
higher bioluminescent signals than 2 106 CFUs, but the
signals of both inocula decreased at a similar rate (Figure 1c
and d). 2 105 CFUs resulted in bioluminescent signals that
increased on day 1 but decreased on subsequent days to
levels below the bioluminescent signals of the other inocula.
It is noteworthy that all three inocula had bioluminescent
signals that were statistically greater than the background
bioluminescence signals (none). As our goal was to produce a
S. aureus skin wound infection that induced relatively small
lesion sizes and bioluminescence signals that were greater
than the uninfected scalpel wounds, the intermediate
inoculum of 2106 CFUs of S. aureus was used in all
subsequent experiments.
To confirm that the in vivo bioluminescence signals
accurately represented the bacterial burden in vivo, colony
counts were performed on skin biopsies harvested on day 1
from the infected skin lesions (Figure 2). The ex vivo bacterial
burden of mice inoculated with 2 105, 2106, and 2107
CFUs (Figure 2a and b) highly correlated with the corre-
sponding in vivo bioluminescence signals (correlation
coefficient: R2¼ 0.9853; Figure 2c). These data demonstrate
that in vivo bioluminescence imaging of a S. aureus skin
wound infection provides a noninvasive and accurate
measurement of the in vivo bacterial burden.
In vivo fluorescence imaging to measure the infection-induced
inflammation
Neutrophil recruitment to the site of infection is required for
an effective immune response against S. aureus (Verdrengh
and Tarkowski, 1997; Molne et al., 2000). To determine
the degree of neutrophil recruitment, histological analysis is
commonly used. At day 1, skin wounds of mice inoculated
with S. aureus developed large neutrophilic abscesses
observed in both hematoxylin and eosin (H&E)-labeled and
anti-Gr-1 mAb (neutrophil marker)-labeled sections com-
pared with control mice that were wounded but not infected
with S. aureus (Figure 3a). In addition, S. aureus bacteria
could be detected within the abscess by Gram stain.
However, the measurement of neutrophil abscess formation
by histology is a nonparametric measurement and requires
euthanasia to obtain skin specimens. To noninvasively
quantify the inflammatory response, in vivo fluorescence
imaging of LysEGFP mice, which possess green fluorescent
neutrophils, was used (Faust et al., 2000). By combining the
use of bioluminescent S. aureus and LysEGFP mice, both
bacterial burden and neutrophil infiltration (Kim et al., 2008)
could be simultaneously measured by sequential in vivo
bioluminescence and fluorescence imaging (Figure 3b–e).
Similar to C57BL/6 mice in Figure 1, S. aureus-inoculated
LysEGFP mice developed bioluminescence signals that
decreased over the course of the infection and were
detectable over the background signals of control uninfected
mice (Figure 3b and d). In addition, the S. aureus-infected
LysEGFP mice had significantly greater enhanced green
fluorescent protein (EGFP)-neutrophil fluorescent signals
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Figure 1. Mouse model of Staphylococcus aureus skin wound infection. Three 8-mm in length, parallel, full-thickness scalpel wounds on the backs of
mice were inoculated with 2105, 2 106, or 2107 colony-forming units (CFUs) per 10ml of S. aureus or no bacteria (none) (n¼ 12 mice per group).
(a) Mean total lesion size (cm2)±SEM. (b) Representative photographs of the lesions of the entire dorsal back (upper panels) and close-up photographs of the
lesions (lower panels) are shown. (c) Bacterial counts as measured by in vivo S. aureus bioluminescence (mean total flux (photons per second)±SEM)
(logarithmic scale). (d) Representative in vivo S. aureus bioluminescence on a color scale overlaid on top of a grayscale image of mice. *Po0.05; wPo0.01;
zPo0.001, S. aureus-infected mice versus none (Student’s t-test).
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compared with uninfected control mice at all days following
inoculation (Figure 3c and e). Therefore, EGFP-neutrophil
fluorescence provides a quantifiable measurement of the
infection-induced inflammatory response.
Contribution of IL-1a and IL-1b to host defense
IL-1R/MyD88 signaling is an essential immune mechanism
required for host defense against S. aureus skin infections in
mice and humans (Miller et al., 2006; von Bernuth et al.,
2008). We previously described that IL-1b (but not IL-1a) has
a crucial role in activating IL-1R-mediated cutaneous host
defense against an intradermal S. aureus challenge in mice
(Miller et al., 2007). Thus, we wanted to determine the
contribution of IL-1a and IL-1b to IL-1R-mediated cutaneous
host defense during the skin wound infection compared
with the deeper intradermal infection. Wild-type mice and
mice deficient in IL-1R, IL-1a, or IL-1b were inoculated with
S. aureus either by superficial inoculation of the scalpel
wounds or by intradermal injection and lesion sizes, and
in vivo bioluminescence were evaluated (Figure 4). IL-1R-
deficient mice developed up to 3-fold larger lesions and 8- to
15-fold higher bioluminescent signals than wild-type mice
(Figure 4a). Similarly, during the deeper intradermal S. aureus
infection, IL-1R-deficient mice developed 3.7-fold larger
lesions and up to 12.8-fold higher bioluminescent signals
than wild-type mice (Figure 4b). However, during the
superficial infection, mice deficient in either IL-1a or IL-1b
had B1.5-fold larger lesions and up to 3-fold higher
bioluminescent signals on days 1 and 3 after inoculation
(Figure 4a). Although these increases were statistically
significant, they were modest compared with the substan-
tially increased lesion sizes and bioluminescent signals
observed in IL-1R-deficient mice. In contrast, for the deeper
intradermal infection, IL-1b-deficient mice had lesion sizes
and bioluminescent signals that were virtually identical to
those of IL-1R-deficient mice, and IL-1a-deficient mice
had lesion sizes and bioluminescent signals that closely
resembled those of wild-type mice (Figure 4b). Taken
together, both IL-1a and IL-1b contributed to IL-1R-mediated
host defense during the S. aureus skin wound infection,
whereas IL-1b was the predominant contributor to IL-1R-
mediated host defense during the deeper intradermal
S. aureus skin infection.
Determination of the in vivo efficacy of topical antimicrobial
therapy
To determine whether this S. aureus skin wound infection
model could be used to evaluate the efficacy of topical
antimicrobial therapy, we compared the efficacy of the two
FDA-approved topical prescription-strength therapies, mupi-
rocin and retapamulin. To perform these studies, we gene-
rated a bioluminescent USA300 strain. This strain was used in
combination with LysEGFP mice so that both the bacterial
burden and infection-induced inflammation could be
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Figure 2. In vivo bioluminescence highly correlated with ex vivo bacterial
colony-forming unit (CFU) counts. Bacteria present within the infected skin
lesions that were inoculated with 2 105, 2106, and 2 107 CFUs per
10ml of Staphylococcus aureus (n¼ 5 mice per group) were harvested from
mice on postinoculation day 1 and CFUs were determined after overnight
culture. (a) Representative bacterial culture plates after overnight culture with
or without bioluminescence. (b) Mean CFUs of S. aureus±SEM recovered
from 8-mm lesional punch biopsies on day 1. (c) Correlation between in vivo
bioluminescence signals and total CFUs harvested from the infected skin
lesions. The logarithmic trendline (blue line) and the correlation coefficient of
determination (R2) between in vivo bioluminescence signals and total CFUs
are shown.
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measured. Mupirocin 2% ointment, retapamulin 1% ointment,
or corresponding vehicle ointments (polyethylene glycol
(mupirocin) and white petrolatum (retapamulin)) was topically
applied (0.1ml volume) to the infected skin lesions at 4 hours
after inoculation followed by twice-daily (every 12hours)
application for the next 7 days (Figure 5). Mupirocin ointment
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Figure 3. In vivo fluorescence imaging to measure the infection-induced inflammation. Three 8-mm in length, parallel scalpel wounds on the backs of
(a) C57BL/6 mice or (b–e) LysEGFP mice were inoculated with 2 106 colony-forming units (CFUs) per 10ml of Staphylococcus aureus or no bacteria (none).
(a) Representative photomicrographs (1 of 3, with similar results) of sections from 8-mm punch biopsies taken at 1 day after wounding±S. aureus infection
labeled with hematoxylin and eosin (H&E) stain, anti-Gr-1 mAb (neutrophil marker), and Gram stain. Scale bars¼ 150 mm. (b) In vivo S. aureus burden as
measured by in vivo bioluminescence imaging (mean total flux (photons per second)±SEM) (logarithmic scale). (c) Infection-induced inflammation (enhanced
green fluorescence protein (EGFP)-neutrophil infiltration) as measured by in vivo fluorescence imaging (mean total flux (photons per second)±SEM).
(d) Representative photographs of in vivo S. aureus bioluminescence. (e) Representative photographs of in vivo EGFP-neutrophil fluorescence.
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in comparison with vehicle ointment had virtually iden-
tical lesion sizes, only slightly lower bioluminescence signals
(B2-fold), and a similar degree of inflammation as measured
by EGFP-neutrophil fluorescence until day 10, when a 40%
decrease was observed (Figure 5a–c). In contrast, retapamulin
ointment resulted in a 37–59% decrease in lesion sizes
beginning at day 1 after inoculation, an 85-fold reduction in
bioluminescent signals by day 3, and in a 24–53% decrease
in EGFP-neutrophil fluorescent signals beginning at day 3
compared with vehicle ointment-treated mice (Figure 5d–f).
Thus, retapamulin ointment was clinically effective against
a USA300 MRSA infection in our in vivo model and far
superior to mupirocin treatment. An in vitro antibiotic
sensitivity assay confirmed that this USA300 strain exhibited
high resistance against mupirocin, as this strain had a 33,000-
fold higher minimal inhibitory concentration of mupirocin
compared with a mupirocin-sensitive MSSA (methicillin-
sensitive S. aureus) strain (SH1000) (625 vs. 0.002mg l–1,
respectively). Taken together, these results demonstrate
that this wound infection model can be used to determine
the in vivo effectiveness of topical therapy against a clinically
relevant MRSA USA300 strain, which will be critical in
the future evaluation of other candidate antimicrobial
therapies.
It should be mentioned that the bioluminescent construct
in this USA300 strain was stable at early time points in vivo,
as 100% of the ex vivo CFUs maintained this construct at
least through day 3 (data not shown), suggesting that the
in vivo bioluminescence signals closely approximated the
actual bacterial burden at the time points when we observed
major differences (days 1–3). However, at days 7 and 10,
76 and 50% of ex vivo CFUs maintained the construct,
suggesting that at these late time points the in vivo
bioluminescence signals may underestimate the actual
bacterial burden.
DISCUSSION
Skin infections caused by S. aureus and MRSA have emerged
as a major public health threat in the United States (McCaig
et al., 2006; Moran et al., 2006). As new and effective
Superficial S. aureus infection
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Figure 4. Contribution of IL-1a and IL-1b to IL-1R-mediated host defense
against Staphylococcus aureus skin infection. IL-1a-, IL-1b-, and
IL-1R-deficient mice and wild-type (wt) mice (n¼ 12 mice per group)
were inoculated with (a) 2 106 colony-forming units (CFUs) per 10 ml of
S. aureus in the superficial S. aureus skin infection model or with (b) an
intradermal injection of 2106 CFUs per 100ml of S. aureus. (Left panels)
Mean total lesion size (cm2)±SEM. (Right panels) In vivo bacterial counts as
measured by mean total flux (photons per second)±SEM. *Po0.05; wPo0.01;
zPo0.001, IL-1a-, IL-1b- or IL-1R-deficient mice versus wt mice (Student’s
t-test).
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Figure 5. In vivo efficacy of mupirocin and retapamulin topical therapy
against USA300, a clinically relevant methicillin-resistant Staphylococcus
aureus (MRSA) strain. Three 8-mm in length, parallel scalpel wounds on the
backs of LysEGFP mice were inoculated with 2106 colony-forming units
(CFUs) per 10 ml of USA300. (a–c) Mupirocin 2% ointment, (d–f) retapamulin
1% ointment, or the corresponding vehicle ointment (polyethylene glycol
(mupirocin) and white petrolatum (retapamulin)) (n¼ 6 mice per group) were
topically applied to the infected skin (0.1ml volume per treatment) at 4 hours
after inoculation followed by twice-daily (every 12 hours) application for the
next 7 days. (a, d) Mean total lesion size (cm2)±SEM. (b, e) Bacterial counts
as measured by in vivo USA300 bioluminescence (mean total flux (photons
per second)±SEM) (logarithmic scale). (c, f) Infection-induced inflammation
(enhanced green fluorescence protein (EGFP)-neutrophil infiltration) as
measured by in vivo fluorescence (total flux (photons per second)±SEM).
*Po0.05; wPo0.01; zPo0.001, antibiotic ointment versus vehicle ointment
(Student’s t-test).
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treatment strategies are needed, a rapid and cost-effective
preclinical animal model is necessary to investigate in vivo
protective immune responses and the efficacy of potential
therapeutics. In this study a mouse model of a S. aureus skin
wound infection was developed in which a bioluminescent
S. aureus or CA-MRSA strain was inoculated into skin
wounds and in vivo bioluminescence and fluorescence
imaging was used to noninvasively track the bacterial burden
and infection-induced inflammation in real-time. Using
this model, we uncovered a key role for IL-1a (in addition
to IL-1b) in the cutaneous immune response in vivo.
Importantly, this model was successfully used to evaluate
the efficacy of topical antibiotic therapy against the clinically
relevant CA-MRSA strain USA300.
In this study, we found that both IL-1a and IL-1b
contributed to host defense during a S. aureus skin wound
infection, whereas IL-1b was more critical during a deeper
intradermal S. aureus skin infection. A recent study demon-
strated that keratinocytes stimulated with S. aureus lipotei-
choic acid and peptidoglycan triggered an autocrine IL-1a
signaling loop, which resulted in continuous production of
neutrophil chemokines (Olaru and Jensen, 2010). In addition,
keratinocytes constitutively express prestores of IL-1a that are
released after nonspecific inflammation or infection (Lee
et al., 1997). Thus, the important role for IL-1a during the skin
wound infection is likely because of the release of the IL-1a
from keratinocytes. In contrast, during the intradermal
infection, the inducible IL-1b response of the bone-marrow-
derived recruited cells of the abscess was a more critical
determinant for host defense (Miller et al., 2007). Taken
together, these results suggest that keratinocytes (and IL-1a)
have a greater role in the cutaneous immune response during
a S. aureus skin wound infection. Future studies will use this
model to investigate other important cutaneous host defense
mechanisms, including the role of pattern recognition
receptors (e.g., Toll-like receptors), cytokine and chemokine
responses, and antimicrobial peptides.
As this model represented a S. aureus infection of open
skin wounds, it provided the opportunity to evaluate the
efficacy of topical antimicrobial therapy. We evaluated the
two FDA-approved prescription-strength topical ointments,
mupirocin and retapamulin, against the clinically relevant
USA300 CA-MRSA strain. We found that mupirocin ointment
provided minimal antimicrobial activity against this USA300
strain, which we confirmed had high in vitro resistance to
mupirocin. In contrast, retapamulin 1% ointment substan-
tially reduced the bacterial burden by day 3 (85-fold),
dramatically decreased the infection-induced inflammation
(450%), and had markedly smaller lesions that healed at a
faster rate. These findings have clear clinical relevance and
demonstrate how the presence of antibiotic resistance can
complicate treatment. As retapamulin was clinically effective
in eradicating S. aureus infection in vivo, these results suggest
that retapamulin could serve as an alternative topical agent to
help treat S. aureus/MRSA skin infections (and perhaps
against nasal colonization), especially given the growing
incidence of mupirocin resistance. Last, when comparing the
vehicle ointments, white petrolatum, the vehicle for retapa-
mulin, enhanced the bacterial burden (Figure 5e), which was
not observed with polyethylene glycol, the vehicle for
mupirocin (Figure 5b). Therefore, the vehicle may also be
an important determinant for the development of future
topical antibiotic therapies.
It should be mentioned that we did not observe a major
difference in virulence with the USA300 strain compared
with the laboratory SH1000 strain in this mouse model. The
reason for this is likely because of differences in susceptibility
between human and mouse cells to cytolytic toxins produced
by USA300 (Diep et al., 2010). One example is PVL, which
lyses human and rabbit neutrophils (but not mouse neutro-
phils), and has been demonstrated to have a critical role in
necrotizing pneumonia in rabbits but not in mice (Bubeck
et al., 2008; Diep et al., 2010). In addition, PVL has been
shown not to be a virulence determinant for skin infections in
mice (Bubeck et al., 2008). Thus, in certain instances
regarding species-specific virulence factors, the use of a
mouse model has some limitations.
Taken together, the mouse model developed in this study
utilized noninvasive in vivo bioluminescence and fluores-
cence imaging to determine the bacterial burden and
infection-induced inflammation without the need for eutha-
nasia. Thus, the use of this model will substantially decrease
animal usage, an important consideration for animal protec-
tion. This model could be used to study mechanisms of
protective cutaneous immune responses and as a preclinical
animal model to investigate and compare the in vivo efficacy
of new topical (or perhaps systemic) antimicrobial therapeu-
tic strategies.
MATERIALS AND METHODS
S. aureus bioluminescent strains
The bioluminescent S. aureus SH1000 strain, ALC2906, which
possesses the shuttle plasmid pSK236 with the pbp2 (penicillin-
binding protein 2) promoter fused to the luxABCDE cassette from
Photorhabdus luminescens, was used as previously described (Miller
et al., 2006). This strain emits bioluminescent signals from live
bacteria in all stages of the S. aureus life cycle. The bioluminescent
MRSA strain, ALC6668, was generated from a clinical USA300
isolate (Stemper et al., 2006) in the same fashion as ALC2906.
Preparation of S. aureus for skin inoculation
S. aureus bioluminescent strains ALC2906 and ALC6668 were
prepared as described (Cho et al., 2010). Briefly, mid-logarithmic
phase bacteria were obtained after a 2-hour subculture of a 1:50
dilution of the overnight culture. Bacterial cells were washed twice and
resuspended in sterile pharmacy grade saline (0.9%) at the indicated
concentrations. CFUs were verified after overnight culture of plates.
Mice
Male mice, 6–8 weeks old, on a C57BL/6 genetic background were
used in all experiments. C57BL/6 wild-type mice and IL-1R-deficient
mice (B6.129S7-Il1r1tm1Imx/J) were obtained from Jackson Labora-
tories, Bar Harbor, ME. In some experiments, LysEGFP mice, which
is a mouse strain that possesses green fluorescent myeloid cells
because of a knock-in of EGFP into the lysozyme M gene, were used
(Faust et al., 2000).
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Mouse model of S. aureus skin wound infection
All procedures were approved by the University of California Los
Angeles Chancellor’s animal research committee. The skin of mice
on the posterior upper back and neck was shaved, and three parallel
8-mm in length full-thickness scalpel cuts (no. 11 blade) were made
into the dermis. The wounds were inoculated with 10 ml of S. aureus
strain ALC2906 (2 105, 2 106, or 2 107 CFUs per 10 ml) or
ALC6668 (2 106 CFUs per 10ml) with a micropipettor. Control
uninfected mice were given a sham inoculation with 10 ml of saline
alone. Measurements of total lesion size (cm2) were made by
analyzing digital photographs using the software program ‘‘Image J’’
(NIH Research Services Branch; http://rsbweb.nih.gov/ij/) and a
millimeter ruler as a reference. In some experiments, a deeper
S. aureus infection was generated by inoculating the backs of mice
with an intradermal injection of S. aureus SH1000 strain (2 106
CFUs per 100ml) in sterile pharmacy-grade saline (0.9%) using a
27-gauge insulin syringe (Cho et al., 2010).
Quantification of in vivo S. aureus (in vivo bioluminescence
and CFUs)
Mice were anesthetized via inhalation of isoflurane (2%) and
in vivo bioluminescence imaging was performed using the Xeno-
gen IVIS imaging system (Caliper Life Sciences) as previously
described (Cho et al., 2010). Data are presented on color scale
overlaid on a grayscale photograph of mice and quantified as
total flux (photons per second) within a circular region of interest
(1 103 pixels) using Living Image software (Xenogen). In some
experiments, to confirm that the in vivo bioluminescence signals
accurately represented the bacterial burden in vivo, S. aureus
CFUs were determined after overnight cultures of homo-
genized (Pro200 Series homogenizer (Pro Scientific, Oxford, CT))
8-mm punch biopsy (Acuderm, Fort Lauderdale, FL) specimens of
lesional skin taken at day 1 after inoculation.
Histological analysis
Mice were euthanized and lesional 8-mm punch biopsy (Acuderm)
skin specimens were bisected and one half was fixed in formalin (10%)
and embedded in paraffin and the other half was embedded in Tissue-
Tek O.C.T. (optimal cutting temperature) compound (Sakura Finetek,
Torrance, CA) and frozen in liquid nitrogen. Paraffin sections (4mm
thick) were cut and stained with hematoxylin and eosin and Gram
stain. Frozen sections (4mm thickness) were cut and were then labeled
with a biotinylated rat anti-mouse Gr-1 mAb (1mgml–1; clone RB6-
8C5; IgG2b isotype; BD Pharmingen, San Diego, CA) or isotype
control mAb using the immunoperoxidase method as previously
described (Cho et al., 2010).
Quantification of neutrophil recruitment to the site of S. aureus
skin wound infection (in vivo fluorescence imaging)
To obtain a measurement of neutrophil infiltration, LysEGFPmice were
used. After in vivo bioluminescence imaging, in vivo fluorescence
imaging was performed by using the Xenogen IVIS (Caliper Life
Sciences). EGFP-expressing cells were visualized using the GFP filter
for excitation (445–490nm) and emission (515–575nm) at an exposure
time of 0.5 seconds (Kim et al., 2008, 2009). Data are presented on
color scale overlaid on a grayscale photograph of mice and quantified
as total flux (photons per second) within a circular region of interest
(1 103 pixels) using Living Image software (Xenogen).
Administration of topical mupirocin and retapamulin ointment
The infected skin wounds were treated topically by applying 0.1ml
of mupirocin 2% ointment (Bactroban; GlaxoSmithKline, Research
Triangle Park, NC), retapamulin 1% ointment (Altabax; Stiefel/
GlaxoSmithKline), or the corresponding vehicle ointment (polyethy-
lene glycol (mupirocin) and white petrolatum (retapamulin)) at
4 hours after S. aureus inoculation followed by twice-daily (every
12 hours) application thereafter for a total of 7 days.
Statistical analysis
Data were compared using Student’s t-test (two tailed). All data are
expressed as mean±SEM. Values of Po0.05 were considered
statistically significant.
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